Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

Earnings Estimate Revisions for Actinium This cancer drug developer is expected to earn -$1.38 per share for the fiscal year ending December 2024, which represents a year-over-year change of 24.6%.

Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ...